JP2022512043A5 - - Google Patents
Info
- Publication number
- JP2022512043A5 JP2022512043A5 JP2021547634A JP2021547634A JP2022512043A5 JP 2022512043 A5 JP2022512043 A5 JP 2022512043A5 JP 2021547634 A JP2021547634 A JP 2021547634A JP 2021547634 A JP2021547634 A JP 2021547634A JP 2022512043 A5 JP2022512043 A5 JP 2022512043A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- protein according
- cancer
- identification number
- sequence identification
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862752293P | 2018-10-29 | 2018-10-29 | |
| US62/752,293 | 2018-10-29 | ||
| US201962811116P | 2019-02-27 | 2019-02-27 | |
| US62/811,116 | 2019-02-27 | ||
| PCT/CN2019/114026 WO2020088459A1 (en) | 2018-10-29 | 2019-10-29 | Novel rationally designed protein compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022512043A JP2022512043A (ja) | 2022-02-01 |
| JP2022512043A5 true JP2022512043A5 (https=) | 2022-10-26 |
| JP7496091B2 JP7496091B2 (ja) | 2024-06-06 |
Family
ID=70462528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021547634A Active JP7496091B2 (ja) | 2018-10-29 | 2019-10-29 | 合理的に設計された新規なタンパク質組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12378295B2 (https=) |
| EP (1) | EP3873945A4 (https=) |
| JP (1) | JP7496091B2 (https=) |
| KR (1) | KR20210087965A (https=) |
| CN (1) | CN113166272B (https=) |
| AU (1) | AU2019371994A1 (https=) |
| BR (1) | BR112021008204A2 (https=) |
| CA (1) | CA3117853A1 (https=) |
| MX (1) | MX2021004916A (https=) |
| SG (1) | SG11202104297XA (https=) |
| TW (1) | TWI840433B (https=) |
| WO (1) | WO2020088459A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12247060B2 (en) | 2018-01-09 | 2025-03-11 | Marengo Therapeutics, Inc. | Calreticulin binding constructs and engineered T cells for the treatment of diseases |
| EP3765517A1 (en) | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| CA3105448A1 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| MX2021002077A (es) * | 2018-08-20 | 2021-05-27 | 1Globe Biomedical Co Ltd | Nuevas composiciones de anticuerpos para la inmunoterapia contra el cáncer. |
| GB2599228B (en) | 2019-02-21 | 2024-02-07 | Marengo Therapeutics Inc | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| CN119039441A (zh) | 2019-02-21 | 2024-11-29 | 马伦戈治疗公司 | 与nkp30结合的抗体分子及其用途 |
| AU2020416273A1 (en) | 2020-01-03 | 2022-07-28 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
| IL298136A (en) | 2020-05-13 | 2023-01-01 | Bonum Therapeutics Inc | Preparations of protein complexes and methods of using them |
| EP4174088A4 (en) * | 2020-06-30 | 2024-01-24 | GI Innovation, Inc. | FUSION PROTEIN COMPRISING AN ANTI-LAG-3 AND IL-2 ANTIBODY AND USE THEREOF |
| US20230242607A1 (en) * | 2020-07-09 | 2023-08-03 | Eutilex Co., Ltd. | Il-2 variants |
| KR20230112632A (ko) | 2020-10-23 | 2023-07-27 | 애셔 바이오테라퓨틱스, 인크. | 면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합 |
| WO2022115865A2 (en) | 2020-11-25 | 2022-06-02 | Xilio Development, Inc. | Tumor-specific cleavable linkers |
| AU2022306974A1 (en) | 2021-07-09 | 2024-01-04 | Bright Peak Therapeutics Ag | Modified il-2 polypeptides for treatment of inflammatory and autoimmune diseases |
| AU2023226512A1 (en) | 2022-02-23 | 2024-08-29 | Bright Peak Therapeutics Ag | Immune antigen specific il-18 immunocytokines and uses thereof |
| CN120518765A (zh) * | 2025-02-08 | 2025-08-22 | 龙启生物科技(上海)有限公司 | 一种结合人CD8β的VHH及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| US20040202995A1 (en) | 2003-04-09 | 2004-10-14 | Domantis | Nucleic acids, proteins, and screening methods |
| CU23923B1 (es) | 2010-11-12 | 2013-07-31 | Ct De Inmunología Molecular | Polipéptidos derivados de la il-2 con actividad agonista |
| SG192673A1 (en) * | 2011-02-10 | 2013-09-30 | Roche Glycart Ag | Mutant interleukin-2 polypeptides |
| RU2769282C2 (ru) * | 2016-06-20 | 2022-03-30 | Кимаб Лимитед | Анти-PD-L1 и IL-2 цитокины |
| CN107915777A (zh) * | 2016-10-09 | 2018-04-17 | 泰州迈博太科药业有限公司 | 一种重组免疫细胞因子及其应用 |
| MY201482A (en) * | 2017-04-03 | 2024-02-26 | Hoffmann La Roche | Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15 |
| JP7148539B2 (ja) * | 2017-04-03 | 2022-10-05 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 免疫抱合体 |
-
2019
- 2019-10-29 TW TW108139140A patent/TWI840433B/zh active
- 2019-10-29 AU AU2019371994A patent/AU2019371994A1/en not_active Abandoned
- 2019-10-29 SG SG11202104297XA patent/SG11202104297XA/en unknown
- 2019-10-29 US US17/288,273 patent/US12378295B2/en active Active
- 2019-10-29 BR BR112021008204-2A patent/BR112021008204A2/pt not_active IP Right Cessation
- 2019-10-29 JP JP2021547634A patent/JP7496091B2/ja active Active
- 2019-10-29 CA CA3117853A patent/CA3117853A1/en active Pending
- 2019-10-29 WO PCT/CN2019/114026 patent/WO2020088459A1/en not_active Ceased
- 2019-10-29 EP EP19878076.9A patent/EP3873945A4/en active Pending
- 2019-10-29 CN CN201980071932.6A patent/CN113166272B/zh active Active
- 2019-10-29 KR KR1020217016193A patent/KR20210087965A/ko not_active Abandoned
- 2019-10-29 MX MX2021004916A patent/MX2021004916A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022512043A5 (https=) | ||
| JP7685095B2 (ja) | 多重特異性抗体とその作製及び使用方法 | |
| US10047163B2 (en) | Multispecific constructs | |
| US7262276B2 (en) | Anti human ovarian cancer-anti CD3 bispecific antibody | |
| JP7549961B2 (ja) | 少なくともｃｄ３及びｈｓａを標的とするヘテロ二量体多重特異性抗体フォーマット | |
| JP7399852B2 (ja) | 多重特異性抗体とその作製及び使用方法 | |
| WO2014180577A1 (en) | Bispecific constructs and their use in the treatment of various diseases | |
| CN111378044B (zh) | 抗体融合蛋白、制备方法及其应用 | |
| JP2021512151A5 (https=) | ||
| JP2023159379A (ja) | Ｐｄ－１とｖｅｇｆを標的とした四価二重特異性抗体、その製造方法および用途 | |
| WO2019196309A1 (zh) | 抗pd-l1抗体及其用途 | |
| JP2022512891A5 (https=) | ||
| JP2020530770A5 (https=) | ||
| KR20240046224A (ko) | 이중특이성 항체 및 그 용도 | |
| JP2021534750A5 (https=) | ||
| KR20240127523A (ko) | 항-cntn4 항체 및 그의 용도 | |
| RU2021112298A (ru) | Полученные путем рационального дизайна новые белковые композиции | |
| CN116874606A (zh) | 一种靶向trop2和cd3的双特异性抗体及其制备方法与应用 | |
| CN117586410A (zh) | 一种结合TNFR2和Claudin18.2的双特异性抗体 | |
| JP2023523760A5 (https=) | ||
| CN120958019A (zh) | 针对人分化簇3蛋白的抗体及其变体 | |
| HK40019010A (en) | Multi-specific antibodies and methods of making and using thereof | |
| HK40054346A (en) | Protease cleavable bispecific antibodies and uses thereof | |
| HK40054346B (en) | Protease cleavable bispecific antibodies and uses thereof | |
| HK40018991A (en) | Multi-specific antibodies and methods of making and using thereof |